Nektar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 137
- Market Cap
- $230M
- Website
- http://www.nektar.com
- Introduction
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA)
- Conditions
- Alopecia Areata
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 38
- Registration Number
- 2023-509981-39-00
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie, Rzeszow, Poland
🇵🇱Prywatna Praktyka Lekarska Ewa Ring, Warszawa, Poland
🇵🇱Klinika Ambroziak Sp. z o.o., Warsaw, Poland
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 366
- Registration Number
- 2023-507456-69-00
- Locations
- 🇭🇷
KBC Zagreb, Grad Zagreb, Croatia
🇭🇷Poliklinika Solmed d.o.o., Grad Zagreb, Croatia
🇭🇷NAFTALAN specijalna bolnica za medicinsku rehabilitaciju, Ivanic-Grad, Croatia
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
- Conditions
- Non-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma
- Interventions
- Drug: NKTR-255 at 1.5 µg/kgDrug: NKTR-255 at 3.0 μg/kgOther: Placebo ComparatorDrug: NKTR-255 at 3.0/6.0 μg/kg
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT05664217
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Phase I Study of LY3471851 in Healthy Participants
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT05565729
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
A Single-Dose Study of LY3471851 in Healthy Participants
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT04998487
- Locations
- 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
- Conditions
- Metastatic Head and Neck CancerRecurrent Head and Neck Cancer
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT04969861
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇦🇹Universitätsklinikum Salzburg, Landeskrankenhaus,, Salzburg, Salzburg Bundesland, Austria
🇬🇷Attikon University General Hospital, Athens, Attiki, Greece
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
- Conditions
- Metastatic Melanoma
- Interventions
- Biological: Bempegaldesleukin (NKTR-214)Biological: NivolumabDrug: ⁸⁹Zr-Df-IAB22M2C
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Nektar Therapeutics
- Registration Number
- NCT04955262
- Locations
- 🇺🇸
Investigational Site - Duarte, Duarte, California, United States
🇺🇸Investigational Site - Portland, Portland, Oregon, United States
🇺🇸Investigational Site - Philadelphia, Philadelphia, Pennsylvania, United States
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 81
- Registration Number
- NCT04677179
- Locations
- 🇺🇸
Dedicated Clinical Research, Litchfield Park, Arizona, United States
🇺🇸I.H.S. Health, LLC, Kissimmee, Florida, United States
🇺🇸Gastroenterology Associates of Pensacola, PA, Pensacola, Florida, United States
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
- Conditions
- Covid-19Coronavirus Disease 2019
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04646044
- Locations
- 🇺🇸
A G A Clinical Trials - HyperCore - PPDS, Hialeah, Florida, United States
🇺🇸New Generation Medical Research, Hialeah, Florida, United States
🇺🇸Clinical Site Partners - Winter Park - HyperCore -PPDS, Winter Park, Florida, United States
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
- Conditions
- Head and Neck Squamous Cell CarcinomaColorectal Cancer
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT04616196
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States